Targeting KIR as a novel approach to improve CAR-NK cell function

Area of Science:

• Immunology
• Cell Therapy
• Oncology

Background:

• Chimeric antigen receptor (CAR) NK cells are a promising cell therapy with a favorable safety profile compared to CAR-T cells.
• Killer cell Immunoglobulin-like Receptors (KIR) are crucial regulators of NK cell activity.
• Targeting KIR is an emerging strategy to optimize CAR-NK cell therapy.

Purpose of the Study:

• To explore strategies for improving CAR-NK cell efficacy by targeting KIR.
• To investigate the role of activating and inhibitory KIR in CAR-NK cell function.
• To assess the potential of KIR-targeted CAR-NK cells for enhanced patient outcomes.

Main Methods:

• Utilizing inhibitory KIR to mitigate NK cell fratricide.
• Downregulating inhibitory KIR on CAR-NK cells to overcome HLA-mediated suppression.
• Selecting CAR-NK cell donors with enriched activating KIR.
• Incorporating activating KIR intracellular domains into novel CAR constructs.

Main Results:

• Pre-clinical studies indicate that targeting KIR can enhance CAR-NK cell efficacy.
• Modulating KIR expression and function offers new avenues for CAR-NK cell optimization.
• These strategies hold potential for improving therapeutic outcomes in patients.

Conclusions:

• Targeting Killer cell Immunoglobulin-like Receptors (KIR) is a viable strategy to enhance CAR-NK cell therapy.
• KIR modulation can improve CAR-NK cell function, reduce fratricide, and overcome immune suppression.
• These advancements pave the way for more effective CAR-NK cell-based treatments.